Pharvaris
Develops oral deucrictibant formulations to treat and prevent hereditary angioedema attacks.
$35.40
After-hours close+0.05 (+0.14%)
At close$35.35(−4.46%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 93.42%65.28M sharesInsiders 2.93%2.05M sharesOther 3.65%2.55M shares
Shares outstanding 69.88M · Float 33.19M · 47.5% free float
Institutions13F, as of Jun 30, 2026
130 holders · 65.28M shares · 23 new positions · 73 increased · 33 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 6.57M | 9.40% | +280.8K | Aug 13, 2026 |
| General Atlantic, L.P. | 6.55M | 9.37% | −1.48M | Aug 14, 2026 |
| Foresite Capital Management Iv, LLC | 4.78M | 6.84% | 0 | Aug 14, 2026 |
| Venbio Partners LLC | 4.64M | 6.64% | +4.1K | Aug 14, 2026 |
| Viking Global Investors LP | 3.65M | 5.23% | 0 | Aug 14, 2026 |
| Eqt Fund Management S.A R.L. | 3.42M | 4.90% | 0 | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 3.38M | 4.83% | +250.0K | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.68M | 3.83% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Viking Global Investors LP | 5.60% | 3.65M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Berndt Modig | director, officer: Chief Executive Officer | 1.08M | 1.55% | Aug 18, 2026 |
| Johannes Gerardus Christiaan Petrus Schikan | director | 315.2K | 0.45% | Jul 1, 2026 |
| Anne Lesage | officer: Chief Early Development | 152.7K | 0.22% | Jul 1, 2026 |
| David W. Nassif | officer: CFO / CLO | 120.3K | 0.17% | May 26, 2026 |
| Annick Deschoolmeester | officer: Chief Human Resources Officer | 92.6K | 0.13% | Mar 18, 2026 |
| Peng Lu | officer: President | 65.2K | 0.09% | Aug 13, 2026 |
| David P. Meeker | director | 65.2K | 0.09% | Mar 18, 2026 |
| Anna Nijdam | officer: Principal Accounting Officer | 46.3K | 0.07% | Jun 8, 2026 |
| Wim Souverijns | officer: Chief Commercial Officer | 45.1K | 0.06% | May 19, 2026 |
| Stefan Andreas Abele | officer: Chief Technical Ops Officer | 35.2K | 0.05% | May 19, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Berndt Modigdirector, officer: Chief Executive Officer | Sale | 2,292 | $34.77 | 130,625 |
| Jul 13, 2026 | Berndt Modigdirector, officer: Chief Executive Officer | Sale | 2,292 | $34.97 | 132,917 |
| Jun 29, 2026 | Anne Lesageofficer: Chief Early Development | Sale · 3 lots | 17,597 | $35.06 | 181,122 |
| Jun 30, 2026 | Anne Lesageofficer: Chief Early Development | Sale · 2 lots | 58,575 | $35.48 | 152,719 |
| Jun 30, 2026 | Johannes Gerardus Christiaan Petrus Schikandirector | Sale | 30,712 | $35.49 | 315,167 |
| Jun 29, 2026 | Johannes Gerardus Christiaan Petrus Schikandirector | Sale · 2 lots | 9,288 | $35.07 | 345,879 |
| Jun 26, 2026 | Peng Luofficer: Chief Medical Officer | Sale | 14,700 | $34.00 | 65,631 |
| Jun 25, 2026 | Peng Luofficer: Chief Medical Officer | Sale · 2 lots | 15,000 | $34.60 | 65,631 |
| Jun 25, 2026 | Anne Lesageofficer: Chief Early Development | Sale · 2 lots | 4,600 | $35.12 | 188,119 |
| Jun 18, 2026 | Peng Luofficer: Chief Medical Officer | Sale | 300 | $34.00 | 65,631 |
CongressHouse and Senate disclosures
Not reported.